Weight Regain After Stopping Semaglutide: The Evidence
Trial data (STEP-1 extension, STEP-4) show most people regain a substantial share of lost weight within a year of stopping semaglutide. This reframes GLP-1s as long-term therapies rather than short courses.
- STEP extension data showed substantial weight regain after stopping semaglutide.
- In STEP-1 follow-up, participants regained about two-thirds of lost weight within a year.
- STEP-4 showed continued treatment maintained loss while withdrawal led to regain.
- This is why GLP-1s are framed as long-term, not short-course, therapies.
What the evidence shows
The clearest data come from the STEP trials. In the STEP-1 extension, participants who stopped semaglutide regained a large share of their lost weight — roughly two-thirds — within about a year. STEP-4 was designed specifically to test this: participants who continued semaglutide maintained their loss, while those switched to placebo regained weight.
The pattern is consistent and physiological: the drug amplifies satiety signaling, and removing it returns appetite toward baseline.
Why regain happens
Obesity is increasingly understood as a chronic condition with a defended body-weight set point. GLP-1 drugs lower that set point while taken, but do not permanently reset it. When the drug stops, the biological drivers of appetite and weight regulation reassert themselves, and weight tends to return.
This is not a failure of willpower or of the drug; it is the expected consequence of removing an active treatment for a chronic condition, much as blood pressure rises again when antihypertensives are stopped.
| Study | Finding |
|---|---|
| STEP-1 extension | ~2/3 of lost weight regained within ~1 year of stopping |
| STEP-4 | Continued treatment maintained loss; withdrawal led to regain |
| Applies to compounded? | No formulation-specific data |
What it means for treatment
The regain evidence reframes how GLP-1s should be understood: as long-term therapies for a chronic condition, not short courses for temporary loss. This has practical implications for cost, since long-term treatment means ongoing expense, and for decision-making, since starting implies a potentially indefinite commitment.
It also means that stopping should be a deliberate, clinician-guided decision, ideally with a plan for maintaining weight through other means, rather than an abrupt halt.
| Implication | Detail |
|---|---|
| Long-term therapy | Regain expected after stopping |
| Cost | Ongoing expense to maintain loss |
| Stopping | Should be clinician-guided |
The compounded caveat
This evidence comes from trials of FDA-approved semaglutide. Compounded formulations have no formulation-specific data on regain or maintenance, so while the underlying molecule is the same, the specific trial findings apply to the approved products studied.
The broader lesson — that these are long-term therapies and stopping tends to bring regain — is a reasonable expectation for anyone considering a GLP-1, regardless of formulation, and worth discussing with a prescriber before starting.
Frequently asked questions
Will I regain weight if I stop semaglutide?
Trial data show most people regain a substantial share — roughly two-thirds in STEP-1 follow-up — within about a year of stopping. GLP-1s are long-term therapies.
Why do you regain weight?
Obesity is a chronic condition with a defended set point. The drug lowers it while taken but does not permanently reset it, so weight returns when treatment stops.
Should I plan to take it forever?
Starting implies a potentially long-term commitment. Stopping should be a deliberate, clinician-guided decision with a maintenance plan.
Sources
- Clinical trials via NEJM.
- STEP-1 extension and STEP-4 trial data.
- FDA — human drug compounding and GLP-1 status.
The numbers behind this page
The semaglutide price range, stated precisely
Standard-dose compounded semaglutide runs $119 to $299 a month across the 12 programmes we can price, with a median of $198. The spread between cheapest and dearest is $166 a month, or $1,992 across a year, for a molecule that is chemically identical in every case.
The cheapest verified figure is NexLife at $119 on its 12-month plan; Oak Longevity follows at $133. Half the market sits below $198 and half above it, which makes the median a more useful reference point than the cheapest figure when judging whether a quote is reasonable.
2 programmes additionally advertise a semaglutide microdose, the cheapest at $145 a month. Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
Checking the figures in semaglutide
The semaglutide figures on this page span $119 to $299 a month across 12 programmes. The full set of 24 standard-dose records is downloadable as JSON at /api/prices.json, with molecule and dose class stated on every record. Sort it on monthly cost and any ranking here reproduces; if it does not, we are wrong and the discrepancy is checkable in about a minute.
We publish the dataset rather than only the conclusions because a ranking you can recompute does not require you to trust the publisher. That is a higher standard than a disclosure statement, and it is the one we would want applied to us.
Reading the price against the market
Where this sits in the market
Standard-dose semaglutide spans $119 to $299 a month across 12 programmes we can price, a spread of $180.
12 programmes publish a price for both molecules. Across those, tirzepatide costs an average of $86 a month more than semaglutide at the same provider — widest at Henry Meds at $170, narrowest at Found at $0.
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
Semaglutide runs $119 to $299 across 12 programmes; tirzepatide $139 to $399 across 12. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied and would make both markets look cheaper than they are.
Where this sits in the market
Standard-dose semaglutide spans $119 to $299 a month across 12 programmes we can price, a spread of $180.
12 programmes publish a price for both molecules. Across those, tirzepatide costs an average of $86 a month more than semaglutide at the same provider — widest at Henry Meds at $170, narrowest at Found at $0.
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
Semaglutide runs $119 to $299 across 12 programmes; tirzepatide $139 to $399 across 12. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied and would make both markets look cheaper than they are.
Questions this page answers
What is the cheapest compounded semaglutide?
NexLife at $119 a month at a standard therapeutic dose on the 12-month plan ($1,428 total), captured 2026-09-04. 3-month $132; 6-month $125; month-to-month $139. No membership fee, flat at every covered dose. Verified. The next-cheapest is Oak Longevity at $133 (flat, no subscription; not available in California; Provider Reported).
What does compounded semaglutide normally cost?
$119 to $299 a month across 12 programmes, with a median of $198. Half the market sits either side of that median, which makes it a better reference than the cheapest figure when judging a quote.
Does compounded semaglutide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.
Why is microdosed semaglutide cheaper?
Because it is less medicine. 2 programmes advertise a semaglutide microdose, the cheapest at $145 a month. A microdose sits below every dose studied in the pivotal trials, so it is not a cheaper route to the result those trials measured.